Summary of the studies reporting on individual patients
| Tumor-specific outcome (per individual patient) | |
| Complete response | 8 (14%) |
| Partial response | 13 (23%) |
| Stable disease | 6 (11%) |
| Progressive disease | 4 (7%) |
| Unspecified | 25 (45%) |
| Type of hyperinflammatory syndrome | |
| CRS | 16 (28%) |
| HLH | 34 (61%) |
| other | 6 (11%) |
| Type of ICI | |
| Pembrolizumab | 21 (38%) |
| Nivolumab | 11 (20%) |
| Ipilimumab | 2 (4%) |
| Atezolizumab | 2 (4%) |
| Ipilimumab+nivolumab | 13 (23%) |
| Cemiplimab | 1 (2%) |
| Ipilimumab+pembrolizumab | 1 (2%) |
| Sintilimab | 2 (4%) |
| Unspecified | 3 (5%) |
| CRS/HLH treatment with IL-6 blockade | |
| Yes | 14 (25%) |
| No | 42 (75%) |
| Rechallenge with ICIs | |
| Yes | 6 (11%) |
| No | 31 (55%) |
| Unspecified | 19 (34%) |
| CRS/HLH outcome | |
| Recovery | 43 (77%) |
| Deceased, related to CRS/HLH | 6 (11%) |
| Deceased, other reasons | 2 (4%) |
| Unspecified | 5 (9%) |
| Time to CRS/HLH onset | |
| Days after last administration* | 9 (3,75-21) |
| Cycles before symptoms onset* | 2(1-3) |
| Type of underlying malignancy | |
| Bladder cancer | 3 (5%) |
| Lung cancer | 15 (27%) |
| Malignant melanoma | 21 (38%) |
| Renal cell carcinoma | 3 (5%) |
| Other | 14 (25%) |
*Numbers given as mean with IQR
CRS, cytokine release syndrome; HLH, hemophagocytic lymphohistiocytosis; ICI, immune-checkpoint inhibitor.